antisense oligonucleotides


FDA advisors split on Biogen’s ALS therapy

Biogen’s chances of getting an FDA approval for its tofersen drug candidate for amyotrophic lateral sclerosis (ALS) patients who have mutations in the SOD1 gene have been

FDA building

FDA delays decision on Biogen's ALS hope tofersen

The FDA is planning to take an additional three months to review Biogen's experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April.